Synthesis and Biological Evaluation of Antisense Oligonucleotides Containing Modified Pyrimidines

Yogesh S. Sanghvi, P. Dan Cook(Ionis Pharmaceuticals (United States)), Glenn D. Hoke(Ionis Pharmaceuticals (United States)), Stanley T. Crooke(Stanley Foundation), Joel F Martin(Ionis Pharmaceuticals (United States)), David J. Ecker(University of Colorado Denver), O. L. ACEVEDO(Ionis Pharmaceuticals (United States)), Susan M. Freier(Ionis Pharmaceuticals (United States)), Christopher K. Mirabelli(Upsher-Smith Laboratories (United Kingdom)), Maryann C. Zounes(Ionis Pharmaceuticals (United States)), Hak‐Kim Chan(The University of Sydney)
Nucleosides and Nucleotides
January 1, 1991
10.1080/07328319108046475
Cited by 14

Related Papers

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
A Multiubiquitin Chain Is Confined to Specific Lysine in a Targeted Short-Lived Protein
|Science|1989|1.5k
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
|The Lancet|2010|905
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
|Journal of Biological Chemistry|1993|770
Analysis of Antibiotic Resistance Genes in Multidrug-Resistant <i>Acinetobacter</i> sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center
|Antimicrobial Agents and Chemotherapy|2006|481